SCHEMBL1362585

SCHEMBL1362585

Cc1nccn1-c1nc(-c2ccc(Cl)cc2)c(CCCOc2ccccc2C#N)o1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ICMT O60725 2/20 0.36
USP2 O75604 1/20 0.34
MAPK1 P28482 1/20 0.34
NMT2 O60551 1/20 0.33
NMT1 P30419 1/20 0.33
CNR1 P21554 1/20 0.33
GCGR P47871 1/20 0.33
PIN1 Q13526 1/20 0.32
FNTA P49354 1/20 0.32
FNTB P49356 1/20 0.32
PGGT1B P53609 1/20 0.32
ALDH1A1 P00352 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
TNK2 Q07912 1/20 0.32
SLC2A2 P11168 1/20 0.32
HTR1A P08908 1/20 0.32
HTR7 P34969 1/20 0.32
TP53 P04637 1/20 0.32
FFAR1 O14842 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203742 0.88 TP53 (0.41) MAPK1GCGRALDH1A1L3MBTL1TDP1
SCHEMBL962882 0.87 MAPT (0.36) ICMTUSP2MAPK1GCGRALDH1A1
SCHEMBL1361418 0.87 MAPT (0.42) MAPK1GCGRL3MBTL1TDP1TP53
SCHEMBL1361746 0.87 GCGR (0.38) GCGRL3MBTL1TDP1TP53MAPT
Hydrochloric Acid SCHEMBL1362475 0.87 TP53 (0.41) MAPK1GCGRALDH1A1L3MBTL1TDP1
SCHEMBL1361779 0.86 GCGR (0.34) GCGRALDH1A1L3MBTL1TDP1TP53
SCHEMBL1362923 0.85 MAPT (0.42) MAPK1GCGRALDH1A1TP53LMNA
SCHEMBL1362902 0.85 GCGR (0.35) ICMTGCGRALDH1A1L3MBTL1TDP1
SCHEMBL1360123 0.85 ALDH1A1 (0.36) GCGRALDH1A1L3MBTL1TDP1TNK2
SCHEMBL1361745 0.85 POLB (0.38) GCGRL3MBTL1TDP1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067453-B2 Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-29 US disclosed
US-20080269219-A1 Neurotrophin production/secretion promoting agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-7396848-B1 oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-08 US disclosed
EP-1206472-B1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-10-01 EP disclosed
US-6605629-B1 Oxazole derivatives; low toxicity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269219-A1 Neurotrophin production/secretion promoting agent BDNF, NGF, NTRK2 ICMT 4797/4885USP2 3564/4885MAPK1 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.